Case Study Finds Sotorasib Effective as First-Line Treatment for NSCLC With the KRAS G12C Mutation

Web Exclusives —May 16, 2023


Lung Cancer

Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths and comprises 85% of lung cancer cases. The most common subtype is adenocarcinoma, accounting for 40% of all lung cancer cases. In adenocarcinoma, the KRAS viral oncogene is the most common mutation, with the KRAS G12C mutation being the most common (13% of lung adenocarcinomas). KRAS G12C mutation leads to accelerated oncogenic pathways and proliferation of cell growth. Sotorasib, adagrasib, and JNJ-74699157 are inhibitors of the KRAS G12C mutation. Sotorasib targets KRAS G12C and irreversibly inhibits it by binding it in the inactive GDP-bound state and inhibiting KRAS signaling.

In the phase 2 CodeBreaK 100 clinical trial, sotorasib demonstrated clinical efficacy in previously treated NSCLC harboring the KRAS G12C mutation. Sotorasib received accelerated approval by the FDA in 2021 for the treatment of patients with previously treated advanced KRAS G12C–mutated NSCLC. A recently published case study reported the use of sotorasib as first-line treatment for advanced KRAS G12C–mutated NSCLC in an 80-year-old woman. The patient was a former smoker with a medical history of chronic obstructive pulmonary disease (COPD), atrial fibrillation, hypertension, and Crohn disease. The patient had a fall that resulted in fractured ribs and pneumothorax, which required the placement of a chest tube. During chest computed tomography (CT) to evaluate injuries from the fall, the patient was found to have a 2.1-cm lung nodule. Further imaging studies found a 2.2-cm mass in the anterior medial right upper lobe. Biopsy of this nodule demonstrated poorly differentiated carcinoma, and further testing found poorly differentiated NSCLC with the KRAS G12C mutation. Because the patient was a poor surgical candidate due to COPD and poor pulmonary reserve, she received stereotactic body radiotherapy. Disease progression was found on imaging, but no metastatic disease was found with brain magnetic resonance imaging. Due to the patient’s advanced age, poor performance status, and multiple comorbidities, she was not a candidate for platinum-based chemotherapy or immunotherapy. Sotorasib was determined to be the most feasible option for this patient. The patient received 960 mg of oral sotorasib daily and tolerated it well with no significant toxicities. At 3-month evaluation, positron emission tomography (PET)/CT imaging found the patient had a complete response to treatment with complete resolution of all sites. On repeat PET/CT scan 6 months after sotorasib treatment initiation, the response was stable, and the patient continued treatment with a stable quality of life.

Source: Iska S, Alley EW. Sotorasib as first-line treatment for advanced KRAS G12C-mutated non-small cell lung carcinoma: a case report. Case Rep Oncol. 2023;16(1):177-181.

Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State